猕猴桃素-D的抗肺癌作用和免疫调节功能  

Anti-lung Cancer Activity and Immunomodulation of Actinidin D

作　　者：安泳潼[1] 沈龙海[1] 尹蓓珮[1] 刘畅[1] 赵正福 

机构地区：[1]中国医药工业研究总院上海医药工业研究院,创新药物与制药工艺国家重点实验室,上海200437 [2]上海科惠医学科技有限公司,上海200233

出　　处：《中国医药工业杂志》2012年第10期842-845,共4页Chinese Journal of Pharmaceuticals

基　　金：上海市科学技术委员会科研计划项目课题资助(09dz1976300)

摘　　要：建立了裸鼠A549肺癌模型和小鼠Lewis肺癌模型,以环磷酰胺为阳性药,考察猕猴桃素-D对肿瘤生长的抑制作用。并以云芝肝泰胶囊为阳性药,测定了猕猴桃素-D对荷Lewis肺癌雌性小鼠的淋巴细胞增殖和NK细胞活性的影响,评价药物对细胞免疫功能的影响。结果表明,与生理盐水组相比,猕猴桃素-D在150～600 mg/kg范围内对裸鼠A549肺癌细胞和小鼠Lewis肺癌细胞的生长有明显抑制作用,且呈剂量相关性;但与环磷酰胺相比,各剂量组的抑瘤率仍较低。中、高剂量的猕猴桃素-D还可显著促进荷Lewis肺癌雌性小鼠脾淋巴细胞增殖作用,升高NK细胞活性,且在提高雌性小鼠机体免疫力方面优于云芝肝泰胶囊。结果提示猕猴桃素-D可能具有继续向抗肿瘤新药开发的潜力。The A549 lung cancer-bearing nude mouse model and Lewis lung cancer-bearing mouse model were established to investigate the tumor growth inhibition of actinidin D with cyclophosphamide as positive drug. The effects of actinidin D on lymphocyte proliferation and NK cell activity of female mice bearing Lewis tumor were investigated with Polystictus glycopeptides capsules as positive drug. The results showed that compared with the saline group, actinidin D had a dose-related tumor growth inhibition on A549 and Lewis lung cancer cells in the concentration range of 150 - 600 mg/kg, while the tumor inhibitory rate of actinidin D groups was lower than that of cyclophosphamide group. The actinidin D in middle- and high-dose （300 and 600 mg/kg） group could significantly enhance lymphocyte proliferation and increase NK cell activity in Lewis cancer-bearing female mice, and this effect was superior to Polystictus glycopeptides capsules. The results suggested that actinidin D might be considered as a potent antitumor drug candidate.

关 键 词：猕猴桃素-D A549肺癌细胞 LEWIS肺癌细胞 抗肿瘤 免疫功能 

分 类 号：R965[医药卫生—药理学]